|
|
|
|
LEADER |
02956 am a22003133u 4500 |
001 |
132701 |
042 |
|
|
|a dc
|
100 |
1 |
0 |
|a Tošić, Isidora
|e author
|
700 |
1 |
0 |
|a Heppler, Lisa N
|e author
|
700 |
1 |
0 |
|a Egusquiaguirre, Susana P
|e author
|
700 |
1 |
0 |
|a Boehnke, Natalie
|e author
|
700 |
1 |
0 |
|a Correa, Santiago
|e author
|
700 |
1 |
0 |
|a Costa, Daniel F
|e author
|
700 |
1 |
0 |
|a Moore, Elizabeth A Grossman
|e author
|
700 |
1 |
0 |
|a Pal, Sharmistha
|e author
|
700 |
1 |
0 |
|a Richardson, Douglas S
|e author
|
700 |
1 |
0 |
|a Ivanov, Alexander R
|e author
|
700 |
1 |
0 |
|a Haas-Kogan, Daphne A
|e author
|
700 |
1 |
0 |
|a Nomura, Daniel K
|e author
|
700 |
1 |
0 |
|a Hammond, Paula T
|e author
|
700 |
1 |
0 |
|a Frank, David A
|e author
|
245 |
0 |
0 |
|a Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid-coated Layer-by-Layer Nanoparticles
|
260 |
|
|
|b American Association for Cancer Research (AACR),
|c 2021-10-04T18:23:32Z.
|
856 |
|
|
|z Get fulltext
|u https://hdl.handle.net/1721.1/132701
|
520 |
|
|
|a The oncogenic transcription factor STAT3 is aberrantly activated in 70% of breast cancers, including nearly all triple-negative breast cancers (TNBCs). Because STAT3 is difficult to target directly, we considered whether metabolic changes driven by activated STAT3 could provide a therapeutic opportunity. We found that STAT3 prominently modulated several lipid classes, with most profound effects on N-acyl taurine and arachidonic acid, both of which are involved in plasma membrane remodeling. To exploit these metabolic changes therapeutically, we screened a library of layer-by-layer (LbL) nanoparticles (NPs) differing in the surface layer that modulates interactivity with the cell membrane. We found that poly-l-glutamic acid (PLE)-coated NPs bind to STAT3-transformed breast cancer cells with 50% greater efficiency than to nontransformed cells, and the heightened PLE-NP binding to TNBC cells was attenuated by STAT3 inhibition. This effect was also observed in densely packed three-dimensional breast cancer organoids. As STAT3-transformed cells show greater resistance to cytotoxic agents, we evaluated whether enhanced targeted delivery via PLE-NPs would provide a therapeutic advantage. We found that cisplatin-loaded PLE-NPs induced apoptosis of STAT3-driven cells at lower doses compared with both unencapsulated cisplatin and cisplatin-loaded nontargeted NPs. In addition, because radiation is commonly used in breast cancer treatment, and may alter cellular lipid distribution, we analyzed its effect on PLE-NP-cell binding. Irradiation of cells enhanced the STAT3-targeting properties of PLE-NPs in a dose-dependent manner, suggesting potential synergies between these therapeutic modalities. These findings suggest that cellular lipid changes driven by activated STAT3 may be exploited therapeutically using unique LbL NPs.
|
546 |
|
|
|a en
|
655 |
7 |
|
|a Article
|
773 |
|
|
|t 10.1158/1535-7163.MCT-20-0505
|
773 |
|
|
|t Molecular Cancer Therapeutics
|